SITC/LinkedIn
Aug 5, 2025, 05:22
Inside Perspectives on Key Topics from Dr. Michael Lotze Like AI, Climate Science and Content Integrity – SITC
Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“Go behind the scenes and access inside perspectives on key topics from the Journal for ImmunoTherapy of Cancer‘s (JITC) Editor-in-Chief Dr. Michael Lotze! In a video interview, Dr. Lotze shares what he looks for in submissions and weighs in on hot topics like AI, climate science and content integrity.
Hear directly from Dr. Lotze.
Read the latest from JITC and stay at the forefront of innovation in immuno-oncology:
- Tumor organoids in immunotherapy: from disease modeling to translational research – Link.
- ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy – Link.
- Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade – Link.
- Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion – Link.”
More posts featuring Society for Immunotherapy of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 06:08
Aug 5, 2025, 05:56
Aug 5, 2025, 05:42
Aug 5, 2025, 05:24
Aug 5, 2025, 04:56
Aug 5, 2025, 04:32